Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (392)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (17)
Highly specialised technologies guidance (10)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (303)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 341 to 350 of 404
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]
Technology appraisal guidance
TBC
Spesolimab for treating generalised pustular psoriasis flares [ID3963]
Technology appraisal guidance
19 March 2025
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
Technology appraisal guidance
TBC
Surgical vessel sealing systems (MT798)
Medical technologies guidance
TBC
Suspected cancer update
Quality standard
TBC
Suspected sepsis: recognition, diagnosis and early management
NICE guideline
TBC
Suspected sepsis: recognition, diagnosis and early management
NICE guideline
13 August 2025
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
Technology appraisal guidance
TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Technology appraisal guidance
15 January 2025
Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments ID5082
Technology appraisal guidance
TBC
Previous page
1
…
33
34
Current page
35
36
37
…
41
Page
35
of
41
Next page
Results per page
10
25
50
All
Back to top